Zobrazeno 1 - 10
of 1 056
pro vyhledávání: '"MaassenVanDenBrink, A"'
Autor:
Tessa de Vries, Dennis Schutter, Antoon van den Bogaerdt, Arnaud Vincent, Ruben Dammers, A. H. Jan Danser, Antoinette MaassenVanDenBrink
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-8 (2024)
Abstract Background Different responses in human coronary arteries (HCA) and human middle meningeal arteries (HMMA) were observed for some of the novel CGRP receptor antagonists, the gepants, for inhibiting CGRP-induced relaxation. These differences
Externí odkaz:
https://doaj.org/article/c5b04f445c0d4cf3b4c4a9bd7aa11ca8
Autor:
Deirdre M. Boucherie, Ruben Dammers, Arnaud Vincent, A. H. Jan Danser, Antoinette MaassenVanDenBrink
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Orally administered second-generation gepants are effective for the treatment of migraine. The intranasal administration of the third-generation gepant zavegepant might have additional benefits including a rapid onset of action, b
Externí odkaz:
https://doaj.org/article/05f6db0a3047442a85aeee2d4265dc6d
Autor:
Jan Versijpt, Christina Deligianni, Muizz Hussain, Faisal Amin, Uwe Reuter, Margarita Sanchez-del-Rio, Derya Uluduz, Deirdre Boucherie, Dena Zeraatkar, Antoinette MaassenVanDenBrink, Simona Sacco, Christian Lampl, Raquel Gil-Gouveia
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Objective The aim of this paper is to critically re-appraise the published trials assessing propranolol for migraine prophylaxis. Methods We report methods and results following the Preferred Reporting Items for Systematic Reviews (PRISMA),
Externí odkaz:
https://doaj.org/article/67ebd502e30b422e98e45bc209d9cb6f
Autor:
Britt W. H. van der Arend, Daphne S. van Casteren, Iris E. Verhagen, Antoinette MaassenVanDenBrink, Gisela M. Terwindt
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-9 (2024)
Abstract Background Currently, there is no evidence-based hormonal treatment for migraine in women. Several small studies suggest a beneficial effect of combined oral contraceptives, but no large randomized controlled trial has been performed. As pro
Externí odkaz:
https://doaj.org/article/ef4c9135932f4f3e914dff3196816ecb
Autor:
Paolo Martelletti, Matilde Leonardi, Messoud Ashina, Rami Burstein, Soo-Jin Cho, Augustina Charway-Felli, David W. Dodick, Raquel Gil-Gouveia, Licia Grazzi, Christian Lampl, Antoinette MaassenVanDenBrink, Mia T. Minen, Dimos Dimitrios Mitsikostas, Jes Olesen, Mayowa Ojo Owolabi, Uwe Reuter, Elena Ruiz de la Torre, Simona Sacco, Todd J Schwedt, Gianluca Serafini, Nirmal Surya, Cristina Tassorelli, Shuu-Jiun Wang, Yonggang Wang, Tissa Wijeratne, Alberto Raggi
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-17 (2023)
Abstract The 2030 Agenda for Sustainable Development sets out, through 17 Sustainable Development Goals (SDGs), a path for the prosperity of people and the planet. SDG 3 in particular aims to ensure healthy lives and promote well-being for all at all
Externí odkaz:
https://doaj.org/article/9767ef7494b74f529cd62eb1844039fa
Autor:
Bianca Raffaelli, David García-Azorín, Deirdre M. Boucherie, Faisal Mohammad Amin, Christina I. Deligianni, Raquel Gil-Gouveia, Sarah Kirsh, Christian Lampl, Simona Sacco, Derya Uluduz, Jan Versijpt, Antoinette MaassenVanDenBrink, Dena Zeraatkar, Margarita Sanchez-del-Rio, Uwe Reuter
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-13 (2023)
Abstract Objective Topiramate is a repurposed first-line treatment for migraine prophylaxis. The aim of this systematic review and meta-analysis is to critically re-appraise the existing evidence supporting the efficacy and tolerability of topiramate
Externí odkaz:
https://doaj.org/article/2aaaf3b978a54374adc03250fc10ac33
Autor:
Christina I. Deligianni, Simona Sacco, Esme Ekizoglu, Derya Uluduz, Raquel Gil-Gouveia, Antoinette MaassenVanDenBrink, Raffaele Ornello, Margarita Sanchez-del-Rio, Uwe Reuter, Jan Versijpt, Tessa de Vries, Muizz Hussain, Dena Zeraatkar, Christian Lampl
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-11 (2023)
Abstract Objective Novel disease-specific and mechanism-based treatments sharing good evidence of efficacy for migraine have been recently marketed. However, reimbursement by insurers depends on treatment failure with classic anti-migraine drugs. In
Externí odkaz:
https://doaj.org/article/d634cb595a454483a4ba81c2d679956b
Autor:
Britt W. H. Van Der Arend, Nancy Van Veelen, Joëlle E. T. De Ruijter, Michael H. Olsen, Antoinette MaassenVanDenBrink, Gisela M. Terwindt
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
BackgroundAnti-CGRP-(receptor-)monoclonal antibodies (anti-CGRP(R)-mAbs) represent a novel class of drugs for migraine treatment, but their long-term cerebrovascular and cardiovascular (CV) safety warrants further examination.MethodsIn this observati
Externí odkaz:
https://doaj.org/article/2d9d031425124ef39c976ba78accff39
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Linda Al-Hassany, Nazia Karsan, Christian Lampl, Peter J. Goadsby, Antoinette MaassenVanDenBrink
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-5 (2023)
Abstract Migraine is a debilitating disorder, and while the introduction of monoclonal antibodies (mAbs) has led to efficacious and tolerable responses, a substantial number of patients are so-called “non-responders”. We introduce reasons for thi
Externí odkaz:
https://doaj.org/article/86103238d77b436aae4d961c4da1e0c8